Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1579-1581

  Mendes, Rodrigo E ^a   Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

ABSSSIs; Bactericidal; Lipoglycopeptides

Indexed keywords

ORITAVANCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORYNEBACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; LISTERIA MONOCYTOGENES; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS; STREPTOCOCCUS BOVIS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS SALIVARIUS; CROSS INFECTION; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEALTH; HOSPITAL; HUMAN; IC50; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; GLOBAL HEALTH; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 84903890948     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku016     Document Type: Article

References (8)

1. The Medicines Company. Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections. Press Release. http://ir.themedicinescompany.com/phoenix.zhtml?c=122204 andandp=irol-newsArticleandandID=1834647andandhighlight= (24 January 2014, date last accessed).
2. Arhin FF, Moeck G, Draghi DC et al. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008. Int J Antimicrob Agents 2010; 36: 474-6.
3. Morrissey I, Seifert H, Canton R et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother 2013; 68: 164-7.
4. Mendes RE, Farrell DJ, Sader HS et al. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012; 54 Suppl 3: S203-13.
5. Arhin FF, Draghi DC, Pillar CM et al. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. Int J Antimicrob Agents 2012; 40: 562-3.
6. Gould IM, David MZ, Esposito S et al. New insights into meticillinresistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012; 39: 96-104.
7. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.